FWBI Opportunities in Multi-Billion-Dollar Commercial Markets

James Sapirstein
Chairman, President and CEO of First Wave BioPharma, Inc.:
"We now have development- and clinical-stage programs that span six GI indications with significant market size opportunities, including: COVID-19-related GI infections (estimated at $10 billion, for COVID-19 related anti-virals); ulcerative colitis, ulcerative proctitis and ulcerative proctosigmoiditis (estimated at $5 billion); Crohn’s disease (estimated at $7.4 billion); immune checkpoint inhibitor-associated colitis (estimated at $22 billion for immune checkpoint inhibitors); and exocrine pancreatic insufficiency (EPI), a dangerous digestive disorder that afflicts most patients with cystic fibrosis and chronic pancreatitis (estimated at $1.6 billion)."

Short term price target: 3.31, medium term: 6.44, end of 2022: 9.5.